Structure–activity exploration of a small-molecule lipid II inhibitor

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2383-2394

  Fletcher, Steven ^a   Yu, Wenbo ^a,b   Huang, Jing ^a,b   Kwasny, Steven M ^c   Chauhan, Jay ^a   Opperman, Timothy J ^c   Mackerell, Alexander D ^a,b   De Leeuw, Erik Ph ^d  

^a Department of Pharmaceutical Sciences ^*  (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c MICROBIOTIX INC   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Computer aided drug design; Lipid II; Phospholipid

Indexed keywords

1 (2 HYDROXYETHYL) 2,4 DIPHENYL 6, [3 (1,3,3 TRIMETHYLINDOLIN 2 YLIDENE)PROP 1 EN 1 YL]PYRIDIN 1 IUM TETRAFLUOROBORATE; 1 ISOBUTYL 2,4 DIPHENYL 6, [3 (1,3,3 TRIMETHYLINDOLIN 2 YLIDENE)PROP 1 EN 1 YL]PYRIDIN 1 IUM TETRAFLUOROBORATE; 1 ISOPROPYL 2,4 DIPHENYL 6, [3 (1,3,3 TRIMETHYLINDOLIN 2 YLIDENE)PROP 1 EN 1 YL]PYRIDIN 1 IUM TETRAFLUOROBORATE; 1 [2 (DIMETHYLAMINO)ETHYL] 2,4 DIPHENYL 6, [3 (1,3,3 TRIMETHYLINDOLIN 2 YLIDENE)PROP 1 EN 1 YL]PYRIDIN 1 IUM TETRAFLUOROBORATE; ANTIINFECTIVE AGENT; BAS 00127538; DEFENSIN; LIPID; METHYL 2,4 DIPHENYL 6, [3 (1,3,3 TRIMETHYLINDOLIN 2 YLIDENE)PROP 1 EN 1 YL]PYRIDIN 1 IUM TETRAFLUOROBORATE; MURAMIC ACID; N ACETYLGLUCOSAMINE; PENTAPEPTIDE; PEPTIDOGLYCAN; POLYPEPTIDE ANTIBIOTIC AGENT; PYRIDINIUM DERIVATIVE; PYROPHOSPHATE; UNCLASSIFIED DRUG; BAS00127538; INDOLE DERIVATIVE; MOLECULAR LIBRARY; MURAMYL-NAC-(PENTAPEPTIDE)PYROPHOSPHORYL-UNDECAPRENOL; PYRAN DERIVATIVE; URIDINE DIPHOSPHATE N ACETYLMURAMIC ACID;

ACINETOBACTER BAUMANNII; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOSYNTHESIS; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; ESCHERICHIA COLI; HYDROPHILICITY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; SYNTHESIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BACTERIUM; CELL LINE; CELL SURVIVAL; DRUG DESIGN; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MOLECULAR LIBRARY;

ANTI-BACTERIAL AGENTS; BACTERIA; CELL LINE; CELL SURVIVAL; DRUG DESIGN; HUMANS; INDOLES; MICROBIAL SENSITIVITY TESTS; PYRANS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; URIDINE DIPHOSPHATE N-ACETYLMURAMIC ACID;

EID: 84929190142     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S79504     Document Type: Article

References (35)

1. Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat Rev Drug Discov. 2006;5:321–332.
2. Labischinski H, Goodell EW, Goodell A, Hochberg ML. Direct proof of a “more-than-single-layered” peptidoglycan architecture of Escherichia coli W7: a neutron small-angle scattering study. J Bacteriol. 1991;173:751–756.
3. McCloskey MA, Troy FA. Paramagnetic isoprenoid carrier lipids. 2. Dispersion and dynamics in lipid membranes. Biochemistry. 1980;19:2061–2066.
4. McCafferty DG, Cudic P, Frankel BA, Barkallah S, Kruger RG, Li W. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers. 2002;66:261–284.
5. Bauer R, Dicks LM. Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol. 2005;101:201–216.
6. Brotz H, Bierbaum G, Reynolds PE, Sahl HG. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem. 1997;246:193–199.
7. McCafferty DG, Cudic P, Yu MK, Behenna DC, Kruger R. Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol. 1999;3:672–680.
8. Ruzin A, Singh G, Severin A, et al. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 2004;48:728–738.
9. Maki H, Miura K, Yamano Y. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45:1823–1827.
10. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23:99–139.
11. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710–720.
12. de Leeuw E, Li C, Zeng P, et al. Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett. 2010;584:1543–1548.
13. Schneider T, Kruse T, Wimmer R, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science. 2010;328:1168–1172.
14. Schmitt P, Wilmes M, Pugnière M, et al. Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J Biol Chem. 2010;285:29208–29216.
15. Sass V, Schneider T, Wilmes M, et al. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun. 2010;78:2793–2800.
16. Varney KM, Bonvin AM, Pazgier M, et al. Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II. PLoS Pathog. 2013;9:e1003732.
17. Brown RD, Martin YC. The information content of 2D and 3D structural descriptors relevant to ligand-receptor binding. J Chem Inf Comput Sci. 1997;37:1–9.
18. Xue L, Godden JW, Stahura FL, Bajorath J. Design and evaluation of a molecular fingerprint involving the transformation of property descriptor values into a binary classification scheme. J Chem Inf Comput Sci. 2003;43:1151–1157.
19. Lichtenstein SJ, Dorfman M, Kennedy R, Stroman D. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2006;43:19–26.
20. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
21. Brooks BR, Brooks CL 3rd, Mackerell AD Jr, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30:1545–1614.
22. Klauda JB, Venable RM, Freites JA, et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J Phys Chem B. 2010;114:7830–7843.
23. MacKerell AD, Bashford D, Bellott M, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 1998;102:3586–3616.
24. Best RB, Zhu X, Shim J, et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ1 and χ2 dihedral angles. J Chem Theory Comput. 2012;8:3257–3273.
25. Jorgensen WL. Transferable intermolecular potential functions for waters, alcohols, and ethers. Application to liquid water. J Am Chem Soc. 1981;103:335.
26. Vanommeslaeghe K, Hatcher E, Acharya C, et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem. 2010;31:671–690.
27. Vanommeslaeghe K, Mackerell AD Jr. Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing. J Chem Inf Model. 2012;52:3144–3154.
28. Vanommeslaeghe K, Raman EP, MacKerell AD Jr. Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges. J Chem Inf Model. 2012;52:3155–3168.
29. Åqvist J, Medina C, Samuelsson JE. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994;7:385–391.
30. Breukink E, van Heusden HE, Vollmerhaus PJ, et al. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J Biol Chem. 2003;278:19898–19903.
31. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard–Eighth Edition. Wayne, PA: CLSI; 2009.
32. Butler MM, Lamarr WA, Foster KA, et al. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother. 2007;51:119–127.
33. Cotsonas King A, Wu L. Macromolecular synthesis and membrane perturbation assays for mechanisms of action studies of antimicrobial agents. Curr Protoc Pharmacol. 2009;Chapter 13:Unit13A17.
34. Macias AT, Mia MY, Xia G, Hayashi J, MacKerell AD Jr. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck. J Chem Inf Model. 2005;45:1759–1766.
35. de Leeuw EP. Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii. Drug Des Devel Ther. 2014;8:1061–1064.